Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT) vs. FMT Enriched with Lactobacillus in the Treatment of Recurrent Clostridioides difficile Infection
Table 1
Demographics, clinical, and treatment characteristics of both groups.
Characteristics
Combined (n = 21)
FMT (n = 13)
FMT-L (n = 8)
Univariate value
Demographics
Age mean (range)
58.9 (17–91)
56.8 (17–91)
62.4 (53–77)
0.764
Female gender n (%)
12 (57.1)
8 (61.5)
4 (50)
0.673
Clinical data
Current recurrence episode, n (%)
First
16 (76.2)
12 (92.3)
4 (50)
0.045
Second
3 (14.2)
0 (0.0)
3 (37.5)
0.133
Third
2 (9.5)
1 (7.7)
1 (12.5)
0.421
Previous antibiotic use
21 (100)
13 (100)
8 (100)
NA
Third-generation cephalosporin
11 (52.3)
6 (46.1)
5 (62.5)
0.659
Fluoroquinolone
7 (33.3)
5 (38.4)
3 (37.5)
0.841
Clindamycin
5 (23.8)
4 (30.7)
2 (25.0)
0.776
Other
5 (23.8)
5 (38.4)
4 (50.0)
0.94
Bowel movements per day, mean (range)
Basal
8.6 (3–20)
8.9 (3–20)
8.4 (3–12)
0.779
Day 2
3.2 (0–9)
3.3 (0–9)
3.25 (2–5)
0.947
Day 90
1.4 (0–3)
1.4 (0–3)
1.5 (0–3)
0.843
Bristol score, mean (range)
Basal
6.5 (5–7)
6.46 (5–7)
6.37 (5–7)
0.803
Day 2
5.4 (1–7)
5.2 (1–7)
5.87 (4–7)
0.342
Day 90
3.6 (0–5)
3.0 (1–4)
4.75 (4–5)
0.073
Total body weight, mean (range)
Basal
63 (38–94)
60.7 (38–94)
71.5 (49–89)
0.216
Day 90
66 (39–94)
63.3 (39–94)
74.3 (50–93)
0.241
Recurrence after FMT
1 (4.8%)
1 (7.7)
0 (0.0)
0.421
Minor adverse events, n (%)
Burping
3 (14.2)
2 (15.4)
1 (12.5)
0.854
Constipation
4 (19)
4 (30)
0 (0.0)
0.241
Vomiting
2 (9)
1 (7.7)
1 (12.5)
0.075
Severe adverse events, n (%)
0 (0)
0 (0.0)
0 (0.0)
NA
The bold value indicates that it is statistically significant because it is lower than 0.05.
